Metagenomi Therapeutics, Inc. (MGX) research
Metagenomi Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.12
- As of
Metagenomi Therapeutics, Inc. (MGX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-22.
As of . Source: SEC EDGAR filings for MGX. Method and limitations.
Share the MGX intelligence card
See MGX live in the terminal
Track MGX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live MGX terminal, freeActive signals for MGX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 26.6%, EPS $-0.73 vs $-0.5767 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 73% of MGX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 73% of MGX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 73% of MGX (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 56% of MGX (2026Q1)
FREE, NO ACCOUNT
Every signal on MGX, as it fires
You are seeing 5 of 8 signals recorded on MGX since 2026-06-03.
The five above landed across 4 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MGX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 59102M104 · 2026Q2 | $883K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 59102M104 · 2026Q2 | $611K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 59102M104 · 2026Q2 | $136K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 59102M104 · 2026Q2 | $21K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MGX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
MGX against its peers
MGX's operating margin of -380.9% ranks in the 65th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | MGX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 25.2M USD | 500000 USD | 71 | 11 |
| Operating margin | -380.9% | -8021.4% | 65 | 9 |
| Net margin | -348.5% | -633.9% | 59 | 10 |
| Return on equity | -55.4% | -109.8% | 75 | 17 |
Peers (21): ATNM, ANVS, MREO, KPTI, ATYR, VERU, GRCE, CELU, HOWL, TVGN, EDSA, IMMP, CRVO, IBO, TIL, ELTX, MCRB, HRTX, FLNA, GNTA, ELOX. Left out: BETRF (period gap), LITS (no annual filing), SEOVF (no annual filing), HYFT (period gap). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (MGX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more MGX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MGXand get the insider, 13F, options, and confluence read in one view.